Home
HRTX
HRTX News

Latest Heron Therapeutics Inc. (HRTX) News on November 21, 2024

GuruFocus.com

9 days ago

Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive ...

Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks

9 days ago

Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Zacks

9 days ago

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Associated Press Finance

9 days ago

Heron Therapeutics: Q3 Earnings Snapshot

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

PR Newswire

9 days ago

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics

Zacks

14 days ago

Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics

Positive Signs As Multiple Insiders Buy Heron Therapeutics Stock

Simply Wall St.

16 days ago

Positive Signs As Multiple Insiders Buy Heron Therapeutics Stock

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

PR Newswire

17 days ago

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?

Zacks

17 days ago

Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

PR Newswire

23 days ago

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

MT Newswires

a month ago

Heron Therapeutics Reaffirms Supply of Ready-to-Administer Nausea Prevention Medications

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

PR Newswire

a month ago

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability

Simply Wall St.

2 months ago

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability

MT Newswires

2 months ago

Heron Therapeutics Receives FDA Approval for Zynrelef Extended-Release Solution

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

PR Newswire

2 months ago

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

2 months ago

Exploring Three High Growth Tech Stocks in the United States

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

PR Newswire

3 months ago

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

Heron Therapeutics Second Quarter 2024 Earnings: EPS Misses Expectations

Simply Wall St.

3 months ago

Heron Therapeutics Second Quarter 2024 Earnings: EPS Misses Expectations

Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

3 months ago

Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Zacks

3 months ago

Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Associated Press Finance

3 months ago

Heron Therapeutics: Q2 Earnings Snapshot

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

PR Newswire

3 months ago

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024

PR Newswire

4 months ago

Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024

While shareholders of Heron Therapeutics (NASDAQ:HRTX) are in the black over 1 year, those who bought a week ago aren't so fortunate

Simply Wall St.

4 months ago

While shareholders of Heron Therapeutics (NASDAQ:HRTX) are in the black over 1 year, those who bought a week ago aren't so fortunate

MT Newswires

4 months ago

Heron Therapeutics Says Non-Opioid Pain Medication to be Included in Proposed Medicare Programs

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

PR Newswire

4 months ago

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know

Zacks

4 months ago

Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

Zacks

4 months ago

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

MT Newswires

5 months ago

Heron Reports Acceptance of Prior Approval Supplement Application for Zynrelef Vial Access Needle

Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner

Zacks

5 months ago

Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

PR Newswire

5 months ago

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

With 55% ownership of the shares, Heron Therapeutics, Inc. (NASDAQ:HRTX) is heavily dominated by institutional owners

Simply Wall St.

5 months ago

With 55% ownership of the shares, Heron Therapeutics, Inc. (NASDAQ:HRTX) is heavily dominated by institutional owners

Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?

Zacks

5 months ago

Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

Zacks

5 months ago

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D

Zacks

5 months ago

FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D

MT Newswires

5 months ago

Connect Biopharma Names New Chief Executive, Chair

Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug

Zacks

5 months ago

Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

Yahoo Finance Video

5 months ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

GlobeNewswire

5 months ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit

Reuters

5 months ago

California seeks company profits in Big Oil climate lawsuit

USA TODAY

5 months ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

GlobeNewswire

5 months ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Business Wire

5 months ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Business Wire

5 months ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

GlobeNewswire

5 months ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease

Zacks

5 months ago

Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease

Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO

Zacks

5 months ago

Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO

Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

Zacks

6 months ago

Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms

Zacks

6 months ago

J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms

Merck (MRK) to Buy Private Ophthalmology Company EyeBio

Zacks

6 months ago

Merck (MRK) to Buy Private Ophthalmology Company EyeBio

Pleasing Signs As A Number Of Insiders Buy Heron Therapeutics Stock

Simply Wall St.

6 months ago

Pleasing Signs As A Number Of Insiders Buy Heron Therapeutics Stock

Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data

Zacks

6 months ago

Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data

MT Newswires

6 months ago

Heron Therapeutics Submits Prior Approval Supplement to the FDA for Zynrelef Vial Access Needle

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

PR Newswire

6 months ago

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Zacks

6 months ago

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?

Zacks

6 months ago

Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?

5 Small Drug Stocks to Buy From a Recovering Industry

Zacks

6 months ago

5 Small Drug Stocks to Buy From a Recovering Industry

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

Zacks

6 months ago

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now?

Zacks

6 months ago

What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now?

Ionis (IONS), Biogen Down on Ending Development of ALS Drug

Zacks

6 months ago

Ionis (IONS), Biogen Down on Ending Development of ALS Drug

FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing

Zacks

6 months ago

FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing

Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Simply Wall St.

6 months ago

Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript

Insider Monkey

6 months ago

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript

Heron Therapeutics First Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

6 months ago

Heron Therapeutics First Quarter 2024 Earnings: Beats Expectations

GuruFocus.com

6 months ago

Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ...

Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Overview: Surpasses Revenue Estimates

GuruFocus.com

6 months ago

Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Overview: Surpasses Revenue Estimates

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks

6 months ago

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates

Zacks

6 months ago

Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates

Associated Press Finance

6 months ago

Heron Therapeutics: Q1 Earnings Snapshot

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates

PR Newswire

6 months ago

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates

Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline

Zacks

7 months ago

Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline

Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know

Zacks

7 months ago

Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Profit Outlook

Simply Wall St.

7 months ago

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Profit Outlook

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

PR Newswire

7 months ago

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

PR Newswire

7 months ago

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

PR Newswire

8 months ago

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Heron Therapeutics Full Year 2023 Earnings: Beats Expectations

Simply Wall St.

8 months ago

Heron Therapeutics Full Year 2023 Earnings: Beats Expectations

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript

Insider Monkey

8 months ago

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

8 months ago

Q4 2023 Heron Therapeutics Inc Earnings Call

Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics

Zacks

8 months ago

Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics

GuruFocus.com

8 months ago

Heron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023

Associated Press Finance

8 months ago

Heron Therapeutics: Q4 Earnings Snapshot

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

PR Newswire

8 months ago

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates

Zacks

8 months ago

Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates

Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Zacks

8 months ago

Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics

Zacks

9 months ago

Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics

5 Small Drug Stocks to Buy From a Rebounding Industry

Zacks

9 months ago

5 Small Drug Stocks to Buy From a Rebounding Industry

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024

PR Newswire

9 months ago

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024

12 Best Rising Penny Stocks To Buy

Insider Monkey

9 months ago

12 Best Rising Penny Stocks To Buy

Investors in Heron Therapeutics (NASDAQ:HRTX) from five years ago are still down 90%, even after 23% gain this past week

Simply Wall St.

9 months ago

Investors in Heron Therapeutics (NASDAQ:HRTX) from five years ago are still down 90%, even after 23% gain this past week

Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?

Zacks

9 months ago

Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?

All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy

Zacks

9 months ago

All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy

Wall Street's Greatest Dividend Stock Just Made History Again, and 99% of Investors Probably Don't Realize It Exists

Motley Fool

10 months ago

Wall Street's Greatest Dividend Stock Just Made History Again, and 99% of Investors Probably Don't Realize It Exists

Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion

Zacks

10 months ago

Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion

Here’s Why Greenlight Decided to Repurchase Viatris (VTRS)

Insider Monkey

10 months ago

Here’s Why Greenlight Decided to Repurchase Viatris (VTRS)

Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nod

Benzinga

10 months ago

Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nod

Yext Recognized by Built In as a 2024 Best Place To Work

Business Wire

10 months ago

Yext Recognized by Built In as a 2024 Best Place To Work

Alpha and Omega Semiconductor Announces Innovatively Designed Double-Sided Cooling DFN 5x6 Package

Business Wire

10 months ago

Alpha and Omega Semiconductor Announces Innovatively Designed Double-Sided Cooling DFN 5x6 Package

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

PR Newswire

10 months ago

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

GlobeNewswire

10 months ago

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

Share on Social Networks: